Ashish Kumar MD, PhD


Ashish Kumar MD, PhD
Asst ProfessorCollege of Medicineashish.kumar@cchmc.orgwebsite
7015 MLC 3333 Burnet Avenue Cincinnati OH 45229
Phone:513-803-2994Fax: 513-636-3549
  • Molecular Biology and Cancer Genetics

General Research Interest

Dr. Kumar’s laboratory is engaged in researching the biology of infant leukemia. Discoveries made in his laboratory have significantly enhanced the current understanding of leukemia.

Research Description

Dr. Kumar's research studies the biology of infant-leukemia to identify novel therapeutic approaches to treat this disease. Infants with leukemia face an exceptionally grim prognosis because the pathogenesis of the disease is different than that seen in older children. Majority of leukemia in infants involve translocations of the MLL gene on chromosome 11q23. Dr. Kumar's lab is studying experimental models of MLL-rearranged leukemia in the laboratory to discover biological pathways that are dysregulated in the leukemic cells. In knock-in MLL-AF9 mice, they have identified several genes that are abnormally upregulated in hematopoietic cells compared to corresponding wild type cells. These genes and pathways are also up-regulated in leukemia cells of human patients. The lab is now studying the role of these activated genes in the pathogenesis of leukemia.

Current Publications

  • Khandelwal P, Lawrence J, Filipovich AH, Davies SM, Bleesing JJ, Jordan MB, Mehta P, Jodele S, Grimley MS, Kumar A, Myers K, Marsh RAThe successful use of alemtuzumab for treatment of steroid-refractory acute graft-versus-host disease in pediatric patients.Pediatr Transplant 18 94-102 2/1/2014
  • Liu X, Chhipa RR, Pooya S, Wortman M, Yachyshin S, Chow LM, Kumar A, Zhou X, Sun Y, Quinn B, McPherson C, Warnick RE, Kendler A, Giri S, Poels J, Norga K, Viollet B, Grabowski GA, Dasgupta BDiscrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK.Proc Natl Acad Sci U S A 111 E435-44 1/28/2014
  • Karkare S, Chhipa RR, Anderson J, Liu X, Henry H, Gasilina A, Nassar N, Roychoudhury J, Clark JP, Kumar A, Pauletti GM, Ghosh PK, Dasgupta BDirect inhibition of retinoblastoma phosphorylation by nimbolide causes cell-cycle arrest and suppresses glioblastoma growth.Clin Cancer Res 20 199-212 1/1/2014
  • Marsh RA, Kim MO, Liu C, Bellman D, Hart L, Grimley M, Kumar A, Jodele S, Myers KC, Chandra S, Leemhuis T, Mehta PA, Bleesing JJ, Davies SM, Jordan MB, Filipovich AHAn intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis.Biol Blood Marrow Transplant 19 1625-31 11/1/2013

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu